title: Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab.
abstract: We presented a case of a 54-year-old woman, who developed sarcoidosis uveitis while on treatment with the tumour necrosis factor α (TNFα) antagonist etanercept for rheumatoid arthritis. Her condition improved, but did not recover completely after the medication was stopped. After starting her on another TNFα antagonist, adalimumab, the uveitis recovered completely. Etanercept and adalimumab are from the same class of medication, but have different effects on other mediators and cells, which may explain these discrepancies.
authors.affiliation: Hywel Dda Health Board, Aberystwyth Eye Centre, Aberystwyth, UK. damidra5@gmail.com
authors.forename: D
authors.initials: D
authors.lastname: Dragnev
authors.forename: D
authors.initials: D
authors.lastname: Barr
authors.forename: M
authors.initials: M
authors.lastname: Kulshrestha
authors.forename: S
authors.initials: S
authors.lastname: Shanmugalingam
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D015864:Panuveitis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor; D012507:Sarcoidosis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068879:Adalimumab; D000068800:Etanercept